Scottsdale, AZNCT07215234Now EnrollingIRB Ready

Geographic Atrophy Clinical Trial in Scottsdale, AZ

Access cutting-edge geographic atrophy treatment through this clinical trial at a research site in Scottsdale. Study-provided care at no cost to qualified participants.

Sponsored by Sanofi

Quick Self-Assessment

See if you qualify for this Scottsdale location

Preparing your pre-screening questions…

Expert Care in Scottsdale

Access geographic atrophy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related geographic atrophy treatment provided free

Apply for This Scottsdale Location

Check if you qualify for this geographic atrophy clinical trial in Scottsdale, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Scottsdale

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Scottsdale site if eligible
  4. 4Begin participation

About This Geographic Atrophy Study in Scottsdale

This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). The core phase duration will be approximately 2 years for each participant. An Extended Follow-Up (EFU) phase of 3 years follows the core phase. The treatment is a one-time intravitreal injection of SAR446597 (or sham as applicable in Part II).

Sponsor: Sanofi

Who Can Participate

Inclusion Criteria

60 years old or above
Participants with diagnosis of GA secondary to age-related macular degeneration (AMD)
Study eye with best corrected visual acuity (BCVA) ETDRS Snellen equivalent for dose escalation (Part I) between 20/40 and 20/320 and for expansion (Part II) equal or better than 20/200
Study eye with GA lesion measuring between 2.5 and 17.5 mm2 for dose escalation (Part I) and between 2.5 and 14.0 mm2 for expansion (Part II). For multifocal disease, study eye with at least one single lesion of more than 1.25mm2 for both Part I and Part II

Exclusion Criteria

GA in the study eye caused by a disease different than AMD
Presence of neovascularization or a history of treatment with an anti vascular endothelial growth factor agent in the study eye
Any condition or treatment (ocular or systemic) or medical or surgical history in the study eye that may prevent visual acuity improvement or interfere with ocular safety or efficacy assessments
Current or history of systemic complement targeting treatment in the past 12 months
Use of ocular corticosteroids for 4 months (for ocular or periocular injections), 6 months (for intraocular implants) or 3 years (for long lasting intraocular implants) prior to screening in the study eye
History of macular laser photocoagulation treatment, photodynamic- or thermotherapy or photo biomodulation in the study eye
History of active ocular infection in the study eye in 6 months prior to screening
Presence of active ocular or periocular infections
Active uncontrolled glaucoma in the study eye
History of uveitis or scleritis in either eye
Previous gene therapy in either eye
Any significant poorly controlled illness that would preclude study compliance and follow up The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Scottsdale?

Yes, this clinical trial (NCT07215234) has an active research site in Scottsdale, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Geographic Atrophy Treatment Options in Scottsdale, AZ

If you're searching for geographic atrophy treatment options in Scottsdale, AZ, this clinical trial (NCT07215234) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Scottsdale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced geographic atrophy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all geographic atrophy clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Scottsdale, AZ

See all rheumatoid arthritis clinical trials recruiting in Scottsdale — not just this study.

Browse Rheumatoid Arthritis Trials in Scottsdale

Ready to Join in Scottsdale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Scottsdale, AZ